



**BioWisdom:  
Activity and Services**

Paul Bradley  
7<sup>th</sup> June, 2010

## Background and Activities

- \* UK-based SME, headquarters in Harston, Cambridge
- \* Team of scientific and IT professionals
- \* 10 years experience in delivering healthcare intelligence to the pharmaceutical industry and academia
- \* Special interest in translational research
  - \* Achieved through the application of intelligent meta data
  - \* Platform comprises the following products:
    - \* SRS: Large scale data integration and delivery
    - \* Metawise: Enterprise content harmonisation
    - \* OmniViz: Advanced data visualisation and analysis
    - \* SIP: Comprehensive drug safety intelligence data
    - \* Sofia: Ontology and intelligence network software

## Interest in 7<sup>th</sup> Framework Programme

- \* Great interest in collaboration
  - \* SIP is a collaboration between ourselves and the pharmaceutical industry
- \* Opportunity to establish new relationships with groups throughout Europe
  - \* Teams with similar research interests
  - \* Complementary areas of expertise
- \* Strong interest in translational research
  - \* Forum for all the necessary disciplines to come together
  - \* Academia, industry, healthcare providers, CROs, IT

## Description of Services

- \* Not currently providing services for an FP7 participant
- \* Involvement in FP6
  - \* AddNeuroMed project, concerned with discovering biomarkers for Alzheimer's disease (AD)
  - \* Provision of IT and bioinformatics support
  - \* Custom installation of SRS platform to manage consortium data
  - \* Designed system for capturing and curating clinical questionnaire data
  - \* Used Sofia platform to propose 7 novel biomarkers of AD
- \* Interaction in FP7 could be any of the following:
  - \* Project lead
  - \* Collaborative partner
  - \* Provision of specialist services

## Example Project Topic for Next Health Call

- \* Concordance of pre-clinical drug safety with observations in man
- \* Improve communications between the pre-clinical and clinical communities
  - \* Produce vast quantities of data in an unstructured format
    - \* Proprietary: Pharma, CROs
    - \* Public domain: Academia, regulatory authorities
  - \* Different terminology
    - \* Controlled and uncontrolled
- \* Requirement for a harmonised view
  - \* Enable more powerful analyses
  - \* Better understand how pre-clinical effects translate into man
    - \* Relationship with therapeutic area, chemical structure, etc.